Medical department: The domestically produced Type A H1N1 influenza vaccine is safe effective

When Chinanews on November 1 the medical department concerned people in charge answered questions on the Type A H1N1 flu pandemic prevention and control and vaccine prophylatic inoculation work said that the clinical trial result and vaccination working practice proved that the Chinese domestic product Type A H1N1 influenza vaccine was safe effective.

It is reported that 10 domestic vaccine production enterprise has implemented the global biggest scale vaccine clinical trial in 7 provinces, 13,000 people have accepted the clinical trial. The test result indicated: Vaccinates a dose 15μg the Type A H1N1 flu decomposition vaccine then to have the effective protective function, the protection ratio surpasses 85%; Specially more importantly, the vaccine security is good, the untoward effect formation rate does not surpass the seasonal influenza vaccine, has not presented the serious untoward effect. Internationally other countries’ clinical trial results also support our country’s clinical trial conclusion.

In early September, authorizes by state food drugs supervision bureau, the Type A H1N1 influenza vaccine official place in operation, China becomes in the world first to complete the vaccine research and development and registration use country. Vaccine research and development effort of China obtains the result, obtained high affirmation of the World Health Organization.

(This article originates: China News)